US FDA publishes guidance on CLIA waivers
This article was originally published in Clinica
The US FDA has published revised guidance for device manufacturers seeking to get their products waived from regulatory oversight under the Clinical Laboratory and Improvement Amendments of 1988 (CLIA) law. In the regulations published to implement the CLIA in 1992, waived tests were defined as simple laboratory examinations and procedures that were cleared by the FDA for home use, or that employ methodologies that -are simple and accurate as to render the likelihood of erroneous result negligible", or that pose no reasonable risk of harm to the patient if the test is performed incorrectly.
You may also be interested in...
The UK’s Artios has linked up with Merck KGaA in a potentially multi-billion dollar deal to collaborate on discovering and developing up to eight oncology drug targets associated with DNA damage response processes, and is also progressing its own lead compounds through its pipeline.
The UK’s rapid authorization of the Pfizer/BioNTech COVID-19 vaccine has sparked a public debate over regulatory processes at some of the world’s key regulatory bodies.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.